{"entity":{"id":"pnt2003","kind":"drug","name":"Lutetium Lu 177 dotatate (PNT2003)","aka":["PNT2003","177Lu-PNT2003"],"tldr":"PNT2003 is a generic version of Lutathera, the radioactive treatment for neuroendocrine tumours of the gut and pancreas. Lantheus licensed it from POINT Biopharma and received tentative FDA approval in March 2026; full approval was waiting on a patent dispute.","summary":"PNT2003 is lutetium Lu 177 dotatate made as a radioequivalent version of Lutathera, which is indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours. Lantheus licensed exclusive worldwide rights (excluding certain territories) from POINT Biopharma in December 2022; Eli Lilly later acquired POINT. On 2 March 2026 Lantheus announced FDA tentative approval of its abbreviated new drug application, meaning the FDA had completed its review, with full approval subject to the end of a 30-month stay in June 2026 triggered by Hatch-Waxman patent litigation. Whether full approval or launch has followed was not confirmed in the sources read, so the record does not mark it approved.","status":"emerging","asOf":"2026-11-03","links":[{"label":"Lantheus: FDA tentative approval for PNT2003, 2 March 2026 (BioSpace copy)","url":"https://www.biospace.com/press-releases/lantheus-receives-fda-tentative-approval-for-lutetium-lu-177-dotatate-pnt2003-radioequivalent-to-lutathera"},{"label":"Lutathera US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55"}],"tags":["pipeline","deal-asset"],"related":["lutathera"],"cancers":["neuroendocrine"],"sections":[],"technologies":["radioligand-therapy"],"targets":["sstr2"],"drugs":[],"companies":["lantheus","point-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit (ClinicalTrials.gov v2 + company press releases)","editedOn":"2026-11-03"},"code":"PNT2003","modality":"Radioligand therapy (beta), generic radioequivalent of Lutathera","mechanism":"A somatostatin-like peptide carrying radioactive lutetium-177 binds somatostatin receptors on neuroendocrine tumour cells and irradiates them from close range. It is intended as a radioequivalent version of Lutathera, whose US label says it binds somatostatin receptors with highest affinity for subtype 2 (SSTR2).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pnt2003/","neighbours":{"drug":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"}],"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"company":[{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/"},{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/"}]}}